Protein Kinase Inhibitors: all 15,278 studies that test it

Page 40 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.

• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisCompletedNCT02958865Phase 2Results posted
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular LymphomaCompletedNCT02956382Phase 1/2Results posted
• A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)CompletedNCT02955212Phase 3Results posted
• Saracatinib and Alcohol DrinkingCompletedNCT02955186Phase 2Results posted
• Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerTerminatedNCT02954991Phase 2Results posted
• Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminatedNCT02954523Phase 1/2Results posted
• Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant RecipientsCompletedNCT02954198Not applicableResults posted
• A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)CompletedNCT02953678Phase 2Results posted
• Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingNCT02947685Phase 3Results posted
• Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaCompletedNCT02947347Phase 3Results posted
• Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma PatientsTerminatedNCT02943473Phase 2Results posted
• Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and GlioblastomaTerminatedNCT02942264Phase 1/2Results posted
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCCompletedNCT02941926Phase 3Results posted
• A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedNCT02937818Phase 2Results posted
• Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal CancerTerminatedNCT02933944Phase 1Results posted
• Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisCompletedNCT02931838Phase 2Results posted
• Ruxolitinib for Premalignant Breast DiseaseCompletedNCT02928978Phase 2Results posted
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerCompletedNCT02928224Phase 3Results posted
• TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaCompletedNCT02927964Phase 1/2Results posted
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus SubjectsCompletedNCT02927457Phase 1Results posted
• A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete RemissionCompletedNCT02927262Phase 2Results posted
• A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic DermatitisCompletedNCT02925117Phase 2Results posted
• Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)CompletedNCT02924376Phase 2Results posted
• Merestinib In Non-Small Cell Lung Cancer And Solid TumorsTerminatedNCT02920996Phase 2Results posted
• Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)TerminatedNCT02920450Phase 1/2Results posted
• A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic CancersCompletedNCT02919696Phase 1Results posted
• A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced DiseaseCompletedNCT02915783Phase 2Results posted
• Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseTerminatedNCT02914600Phase 3Results posted
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseCompletedNCT02914561Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative ColitisCompletedNCT02914522Phase 3Results posted
• A Study of LY3337641 in Healthy Male ParticipantsCompletedNCT02914379Phase 1Results posted
• Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell TransplantationCompletedNCT02913261Phase 3Results posted
• Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT02910583Phase 2Results posted
• A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusCompletedNCT02908100Phase 2Results posted
• Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast CancerTerminatedNCT02907918Phase 2Results posted
• Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI FailureTerminatedNCT02906696Phase 2Results posted
• Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaCompletedNCT02902965Phase 2Results posted
• Study of Nintedanib and Chemotherapy for Advanced Pancreatic CancerTerminatedNCT02902484Phase 1/2Results posted
• Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung CancerTerminatedNCT02899728Phase 2Results posted
• Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney CancerCompletedNCT02899078Phase 1/2Results posted
• Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerCompletedNCT02898116Phase 1/2Results posted
• Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryCompletedNCT02893930Phase 2Results posted
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerActive, not recruitingNCT02893917Phase 2Results posted
• A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionCompletedNCT02891603Phase 1/2Results posted
• Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian CancerCompletedNCT02889900Phase 2Results posted
• Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateCompletedNCT02889796Phase 3Results posted
• Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX TherapyCompletedNCT02886728Phase 3Results posted
• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in ChildrenTerminatedNCT02885324Phase 2Results posted
• Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With MethotrexateCompletedNCT02885181Phase 2Results posted
• A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy ParticipantsCompletedNCT02884089Phase 1Results posted
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsCompletedNCT02883049Phase 3Results posted
• A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid TumorsTerminatedNCT02880371Phase 1/2Results posted
• Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)CompletedNCT02878057Phase 2Results posted
• Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerCompletedNCT02876302Phase 2Results posted
• Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the ElderlyCompletedNCT02874924Phase 2Results posted
• TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02874404Phase 2Results posted
• A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair DeficiencyCompletedNCT02873975Phase 2Results posted
• Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentCompletedNCT02873936Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)CompletedNCT02872714Phase 2Results posted
• Palbociclib With Everolimus + Exemestane In BCCompletedNCT02871791Phase 1/2Results posted
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantCompletedNCT02869633Phase 2Results posted
• Carfilzomib and TGR-1202 in Treatment of R/R LymphomaTerminatedNCT02867618Phase 1/2Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Phase 2Results posted
• SCHEDULE Follow Up Visit 5-7 yrCompletedNCT02864706Phase 4Results posted
• Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerCompletedNCT02860000Phase 2Results posted
• Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLITerminatedNCT02859727Phase 2/3Results posted
• Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)CompletedNCT02856893Phase 2Results posted
• Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)CompletedNCT02854631Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)CompletedNCT02853331Phase 3Results posted
• A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque PsoriasisCompletedNCT02852967Phase 2Results posted
• Study of Tesevatinib Monotherapy in Patients With Recurrent GlioblastomaCompletedNCT02844439Phase 2Results posted
• Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in ChinaCompletedNCT02842749Phase 4Results posted
• A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host DiseaseCompletedNCT02841995Phase 2Results posted
• Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790MCompletedNCT02841579Phase 2Results posted
• Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous NeurofibromaCompletedNCT02839720Phase 2Results posted
• A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02838420Phase 3Results posted
• Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02834780Phase 1Results posted
• Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT02834390Phase 1Results posted
• A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT02834247Phase 1Results posted
• Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)CompletedNCT02833350Phase 2Results posted
• Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid ArthritisCompletedNCT02831855Phase 4Results posted
• AZD2014 In NF2 Patients With Progressive or Symptomatic MeningiomasCompletedNCT02831257Phase 2Results posted
• A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid TumorsTerminatedNCT02829723Phase 1/2Results posted
• Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT02824029Phase 2Results posted
• Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaTerminatedNCT02819804Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT02819635Phase 2/3Results posted
• Topical Tofacitinib for the Treatment of Alopecia Areata and Its VariantsCompletedNCT02812342Phase 2Results posted
• Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaActive, not recruitingNCT02811861Phase 3Results posted
• Topical Ruxolitinib for the Treatment of VitiligoCompletedNCT02809976Phase 2Results posted
• Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss TreatmentTerminatedNCT02809118Phase 3Results posted
• Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid TumorsCompletedNCT02808650Phase 1Results posted
• A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)CompletedNCT02806947Phase 2Results posted
• A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy VolunteersCompletedNCT02804399Phase 1Results posted
• Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung CancersCompletedNCT02803203Phase 1/2Results posted
• A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02801578Phase 2/3Results posted
• A Phase 1/2 Trial of SRA737 in Subjects With Advanced CancerCompletedNCT02797964Phase 1/2Results posted
• Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesCompletedNCT02795182Phase 1Results posted
• Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
• Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy VolunteersCompletedNCT02792829Phase 1Results posted

← Protein Kinase Inhibitors overview